Company profile
Senti Biosciences Holdings, Inc.
NASDAQ:SNTIBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06325748 | phase1 | active_not_recruiting | 2024-04-22 | 2026-02-01 | Senti Biosciences | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS |
FDA applications (0)
No records yet.